
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil 23 May 2023
May 23, 2023PDF VersionNEW YORK, May 23, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics,... Read more
May 23, 2023PDF VersionNEW YORK, May 23, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics,... Read more
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology... Read more
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24%... Read more
Apr 28, 2023PDF VersionNEW YORK, April 28, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics,... Read more
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Participate now in The Danish Biotech Salary Survey to find out. Finding the right balance between salary... Read more
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or... Read more
Q4 2022 DANYELZA® record net product revenues of $16.4 million, driving YoY growth of 71% and 31%... Read more
Oslo Norway, March 23, 2023 Today LINK Medical has announced the integration of Pharm Assist into the... Read more